Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

A comparative study of zoledronic acid and once weekly Alendronate in the management of acute Charcot arthropathy of foot in patients with diabetes mellitus.

Bharath R, Bal A, Sundaram S, Unnikrishnan AG, Praveen VP, Bhavani N, Nair V, Jayakumar RV, Kumar H.

Indian J Endocrinol Metab. 2013 Jan;17(1):110-6. doi: 10.4103/2230-8210.107818.

2.

Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass.

Hadji P, Gamerdinger D, Spieler W, Kann PH, Loeffler H, Articus K, Möricke R, Ziller V.

Osteoporos Int. 2012 Feb;23(2):625-33. doi: 10.1007/s00198-011-1583-4. Epub 2011 Mar 26.

PMID:
21442459
3.

The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy: a pilot randomized controlled trial.

Pakarinen TK, Laine HJ, Mäenpää H, Mattila P, Lahtela J.

Diabetes Care. 2011 Jul;34(7):1514-6. doi: 10.2337/dc11-0396. Epub 2011 May 18.

4.

Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass.

Hadji P, Ziller V, Gamerdinger D, Spieler W, Articus K, Baier M, Moericke R, Kann PH.

Osteoporos Int. 2012 Jul;23(7):2043-51. doi: 10.1007/s00198-011-1834-4. Epub 2011 Nov 16.

PMID:
22086310
5.
6.

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.

McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.

Bone. 2007 Jul;41(1):122-8. Epub 2007 Mar 24.

PMID:
17468062
7.

Acute Charcot arthropathy in patients with diabetes mellitus: healing times by foot location.

Sinacore DR.

J Diabetes Complications. 1998 Sep-Oct;12(5):287-93.

PMID:
9747646
8.

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.

Clin Ther. 2009 Apr;31(4):751-61. doi: 10.1016/j.clinthera.2009.04.018.

PMID:
19446148
9.

Sympathetic neuropathy in diabetes mellitus patients does not elicit Charcot osteoarthropathy.

Christensen TM, Simonsen L, Holstein PE, Svendsen OL, Bülow J.

J Diabetes Complications. 2011 Sep-Oct;25(5):320-4. doi: 10.1016/j.jdiacomp.2011.06.006. Epub 2011 Aug 2.

PMID:
21813289
10.

Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.

Craig SJ, Youssef PP, Vaile JH, Sullivan L, Bleasel JF.

Intern Med J. 2011 Feb;41(2):186-90. doi: 10.1111/j.1445-5994.2010.02198.x.

PMID:
20214696
11.

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.

Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS.

J Bone Miner Res. 2010 Oct;25(10):2239-50. doi: 10.1002/jbmr.119.

12.

Charcot neuro-osteoarthropathy-current standards.

Petrova NL, Edmonds ME.

Diabetes Metab Res Rev. 2008 May-Jun;24 Suppl 1:S58-61. doi: 10.1002/dmrr.846. Review.

PMID:
18442182
13.

Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.

Woodis CB.

Ann Pharmacother. 2008 Jul;42(7):1085-9. doi: 10.1345/aph.1K652. Epub 2008 May 27.

PMID:
18505912
14.

Effect of immobilization, off-loading and zoledronic acid on bone mineral density in patients with acute Charcot neuroarthropathy: a prospective randomized trial.

Pakarinen TK, Laine HJ, Mäenpää H, Kähönen M, Mattila P, Lahtela J.

Foot Ankle Surg. 2013 Jun;19(2):121-4. doi: 10.1016/j.fas.2012.12.007. Epub 2013 Feb 20.

PMID:
23548455
15.

Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).

Kraj M, Pogłód R, Maj S, Pawlikowski J, Sokołowska U, Szczepanik J.

Acta Pol Pharm. 2002 Nov-Dec;59(6):478-82.

16.

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.

Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC 2nd, Kaur A, Thompson DE, Yates J, Orloff JJ.

Aging (Milano). 2000 Feb;12(1):1-12.

PMID:
10746426
17.

Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D.

N Engl J Med. 2005 Sep 1;353(9):898-908.

18.

A multicenter randomized double-masked comparative study of different preparations of alendronate in osteoporosis - monthly (four weeks) intravenous versus once weekly oral administrations.

Shiraki M, Nakamura T, Fukunaga M, Sone T, Usami A, Inoue T.

Curr Med Res Opin. 2012 Aug;28(8):1357-67. doi: 10.1185/03007995.2012.709838. Epub 2012 Jul 20.

PMID:
22769235
19.

Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.

McKeage K, Plosker GL.

Pharmacoeconomics. 2008;26(3):251-68. Review.

PMID:
18282018
20.

The effectiveness of non-surgical interventions in the treatment of Charcot foot.

Smith C, Kumar S, Causby R.

Int J Evid Based Healthc. 2007 Dec;5(4):437-49. doi: 10.1111/j.1479-6988.2007.00081.x.

PMID:
21631804
Items per page

Supplemental Content

Write to the Help Desk